Buffalo Biomedical Technology co., Ltd.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
Buffalo Biomedical Technology co., Ltd. is dedicated to developing drug-free, side-effect-free innovative medical devices, specializing in critical care treatment fields such as Acute Respiratory Distress Syndrome (ARDS) and Catheter-Associated Urinary Tract Infections (CAUTI).
The world's first "lung perfusion fluid" can be precisely irrigated into the lungs via bronchoscopy to rapidly clear inflammatory factors, reduce edema, and alleviate alveolar infiltration. Animal trials have demonstrated its potential to improve the survival rate of ARDS patients, and the technology has been granted patents in Taiwan, Japan, and Australia. Additionally, the company has licensed the "bladder perfusion fluid" technology, which, through periodic bladder irrigation, effectively alleviates catheter-associated infections, benefiting long-term care and high-risk populations.
Buffalo Biomedical Technology co., Ltd. has also established the "Bufflex" brand, launching medical-grade TVOC adsorption technology to effectively eliminate harmful gases. Suitable for hospitals, long-term care facilities, and sensitive care environments, it delivers comprehensive health protection and demonstrates a steadfast commitment to the quality of life.
(The content above was translated by AI.)
The world's first "lung perfusion fluid" can be precisely irrigated into the lungs via bronchoscopy to rapidly clear inflammatory factors, reduce edema, and alleviate alveolar infiltration. Animal trials have demonstrated its potential to improve the survival rate of ARDS patients, and the technology has been granted patents in Taiwan, Japan, and Australia. Additionally, the company has licensed the "bladder perfusion fluid" technology, which, through periodic bladder irrigation, effectively alleviates catheter-associated infections, benefiting long-term care and high-risk populations.
Buffalo Biomedical Technology co., Ltd. has also established the "Bufflex" brand, launching medical-grade TVOC adsorption technology to effectively eliminate harmful gases. Suitable for hospitals, long-term care facilities, and sensitive care environments, it delivers comprehensive health protection and demonstrates a steadfast commitment to the quality of life.
(The content above was translated by AI.)
Founded Year
2020
Unified Business No.
83083049
Status
Active
Number of Employees
4
Total Paid-in
Capital
45,356,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Buffalo Biomedical Technology co., Ltd. was established in 2020. We focus on developing innovative physical medical solutions, particularly for high-risk patients with acute respiratory distress syndrome (ARDS) and catheter-associated urinary tract infections (CAUTI). Our core technology is a non-specific carbon-based adsorption platform. This innovative technology was initially successfully established to assist severe COVID-19 patients and is now widely applied. Unlike traditional drugs, our products operate through a purely physical adsorption mechanism, carry no risk of drug resistance, and possess excellent biocompatibility. They can be safely and effectively used in synergy with existing treatments, providing patients with a safe, effective, and side-effect-free new therapeutic option. Buffalo Biomedical Technology co., Ltd. is committed to filling unmet clinical needs in the current healthcare system, bringing truly beneficial innovative therapies to critically ill patients, and improving patients' quality of life.
(The content above was translated by AI.)
(The content above was translated by AI.)
